Felipe Montoro Jens Future Plan for Education Overview

The Public-Private Partnership and what is happening today in Brazil is a model that was once celebrated in another part of the country. In Belo Horizonte, capital of Minas Gerais, this was accomplished by the development of its own child-care network and was completed in July 2012. To keep up with the demand, many things are needed in the Child Care Sector. A plan was developed for Rio de Janeiro to construct, maintain, and take care of what was needed for the city to thrive. Another addition to this current project was the 20,000 new places in day-care centers and 40,000 new places in pre-schools.

The International Finance Corporation, is the place responsible for the services through a Public-Private Partnership. This institution is actually the largest to partner with developments such as the PPP, as the IFC is the largest private sector developer in developing nations.The IFC was hired for R $2.3 million and is working closely to ensure every level of construction is done in accordance to the year 2020 deadline. Resources, expertise, innovative thinking and experience globally are some of the positives you can trust when it comes to what they will bring to the table.

All in all, this project that is underway for Rio’s Child Education Network is no small one by any means. It takes groups of all different kinds of individuals to ensure the process is completed to the best of it’s adherence to said guidelines. The Public-Private Partnerships were created by Law No. 11,079 in the year 2004. That December, it established many guidelines for the bidding and contracting of the Public Private Partnership within this public administration. Felipe Monotoro Jens explains this and more with regard to the entities of the public administration as well as the private partners.

Clay Siegall Makes Seattle Genetics An Authority In The Biotechnology Industry

Clay Siegall is the CEO of the Seattle-based biotech firm, Seattle Genetics. His company specializes in developing targeted therapy drugs for diseases that have not had considerable mortality improvements in years. Siegall is a proud alumnus of the revered University of Maryland where he graduated with a BS in zoology. He also holds a PhD in genetics from the world-renowned George Washington University.

After incorporating Seattle Genetics in 1998, Siegall has guided the company to ranks as one of the leading companies in the targeted therapy industry. Under his leadership, Seattle Genetics developed the first FDA-approved antibody drug conjugate. Presently, it has several approved indications. The company is also developing a full-bodied pipeline of over 20 drugs besides engaging in some strategic partnerships with well-known drug manufacturers, including Genentech and Pfizer.

Under Siegall’s transformative leadership, Seattle Genetics has evolved from a small startup with a handful of researchers to an actual power player in the cancer research industry. Moreover, Siegall has impressive plans for Seattle Genetics. With an ever growing list of drugs being developed and number of potential indications, the company is well-positioned to engage in developing viable therapies for the 21st century.

He believes that conventional cancer treatment means like systematic chemotherapies will end up in the historic dustbin. As the efficacy and value of targeted therapies becomes apparent in years ahead, Siegall believes that the traditional therapies will be succeeded by the more tolerable and broadly effective targeted drugs.

About Clay Siegall

Clay Siegall co-established Seattle Genetics. He serves as the company’s chairman. Previously, Dr. Siegall worked for National Cancer Institute and the National Institute of Health. In addition, he rendered his services for Bristol-Myers Squibb Pharmaceutical Research Institute.

Dr. Clay Siegall has authored over 70 publications. Additionally, he holds more than 15 patents. He serves on the board of directors of Alder BioPharmaceuticals, a leading private biotechnology company. One of Dr. Siegall’s accomplishments is leading Seattle Genetics in developing anti-body cancer therapies like ADCETRIS. He has also guided the company’s capital raising activities. Through his efforts, Clay has helped Seattle Genetics to secure more than $675 million from private and public financing, including the firm’s Initial Public Offering (IPO) in 2001.